Sally Arai
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Blood and Marrow Transplant Program 300 Pasteur Drive H0101, MC 5623 Stanford, CA 94305 Tel Work (650) 723-0822 Fax (650) 725-8950
- Academic Offices
Personal Information Email Tel (650) 723-0822Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Blood and Marrow Transplant
- Cancer> Hematology
- Blood and Marrow Transplantation
- Hematology
Honors and Awards
- K23-Reduce GVHD and Relapse using Ex-Vivo Expanded Allogeneic Cell Therapy, NIH (2003-2008)
- A phase I/II study of post-transplant autologous CIK cells for high-risk hematologic malignancies, Cancer Treatment Research Foundation (2005-2009)
Professional Education
| Fellowship: | John Hopkins Hospital MD (1999) |
| Fellowship: | Mount Sinai Medical Center NY (1998) |
| Residency: | Strong Memorial Hospital NY (1995) |
| Internship: | Strong Memorial Hospital NY (1993) |
| Medical Education: | Dartmouth Medical School NH (1991) |
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.
Clinical Trials
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) for Prevention of Hodgkin Lymphoma Progression (The AETHERA Trial) Recruiting
- Defibrotide for Hematopoietic SCT Patients With Severe Hepatic VOD: a Treatment IND Study Recruiting
- Longitudinal Study of Immune Mediated Disorders After Allogeneic HCT Protocol Recruiting
- Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
Publications
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant. 2011; (2): 192-9
- Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. Br J Haematol. 2010; (5): 637-9
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2010; (8): 1145-54
- Rituximab in hematopoietic cell transplantation. Expert Opin Biol Ther. 2010; (6): 971-82
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009; (5): 1099-109
Help